IMUNON INC. - COMMON

IMUNON Announces Leadership Change

12 Mar 2024 17:00:00 By Nasdaq GlobeNewswire

Independent Lab Confirms Immunogenicity and Protection with IMUNON’s IMNN-101 in a Live Virus Challenge Against SARS-CoV-2 Variant XBB.1.5

29 Feb 2024 08:30:00 By Nasdaq GlobeNewswire

Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON’s IMNN-001 in Combination with Bevacizumab in Advanced Ovarian Cancer

27 Feb 2024 08:30:00 By Nasdaq GlobeNewswire

IMNN-101 Preclinical Data in SARS CoV-2 Published in Peer-Reviewed Journal Vaccine

22 Feb 2024 08:00:00 By Nasdaq GlobeNewswire

IMUNON Appoints Dr. Sebastien Hazard as Chief Medical Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

11 Dec 2023 08:30:00 By Nasdaq GlobeNewswire

IMUNON’s VP of R&D to Present at the Vaccines Summit-2023

14 Nov 2023 09:00:00 By Nasdaq GlobeNewswire

IMUNON Reports Third Quarter 2023 Financial Results and Provides a Business Update

14 Nov 2023 08:00:00 By Nasdaq GlobeNewswire

IMUNON to Hold Third Quarter 2023 Financial Results and Business Update Conference Call on Tuesday, November 14, 2023

07 Nov 2023 08:30:00 By Nasdaq GlobeNewswire

IMUNON’s Chief Science Officer to Present at the 3rd International Vaccines Congress

23 Oct 2023 08:30:00 By Nasdaq GlobeNewswire

IMUNON CEO Dr. Corinne Le Goff to Participate in a Panel Discussion on Pandemic Preparedness at the United Nations

19 Oct 2023 08:30:00 By Nasdaq GlobeNewswire

IMUNON Announces First Patient enrolled in Phase 1/2 Clinical Trial of IMNN-001 in Combination with bevacizumab in Advanced Ovarian Cancer

18 Oct 2023 08:30:00 By Nasdaq GlobeNewswire

IMUNON Appoints Dr. Patrick Ott to its Scientific Advisory Board

06 Oct 2023 08:30:00 By Nasdaq GlobeNewswire